Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12420353 | 0.76 | L3MBTL1 (0.32) | POLB | |
| SCHEMBL14300996 | 0.76 | L3MBTL1 (0.32) | POLB | |
| SCHEMBL10174635 | 0.76 | L3MBTL1 (0.32) | POLB | |
| Trifluoroacetic Acid SCHEMBL27130994 | 0.75 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL30302229 | 0.75 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL16718050 | 0.72 | CHIT1 (0.31) | — | |
| Trifluoroacetic Acid SCHEMBL30388501 | 0.72 | CHIT1 (0.31) | — | |
| SCHEMBL800660 | 0.71 | — | — | |
| SCHEMBL14215823 | 0.71 | CA2 (0.38) | CA2ALDH1A1POLBSMN1; SMN2MLYCD | |
| Trifluoroacetic Acid SCHEMBL8326750 | 0.70 | CA14 (0.42) | SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511039-B2 | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INCORPORATED (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | SERPINB1, SERPINE1, SERPINA2 | CA2 3894/4885ALDH1A1 4098/4885POLB 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.